Drug target discovery
Find and prioritize protein targets with proteomics evidence.
DNA and RNA are limited surrogates for what a protein is actually doing. Its level, its modifications, its interactions, whether a compound engages it at all. Target discovery gets sharper when you can see that functional layer directly. Our discovery-scale mass spectrometry platform routinely quantifies thousands of proteins per sample, giving you the statistical power to separate real signal from biological noise. We combine expression, interaction, and modification data to nominate and rank candidate targets, including surface-exposed proteins tractable for modern modalities, and hand you decision-ready prioritization rather than a long list.
Interested in oncology? We profile tumor tissue and healthy adjacent tissue to find novel candidates that no one else saw before. Profiling is possible on the full proteome level or the phosphoproteome level, to identify not only expression changes but also alterations in signaling pathways.
No samples at hand? We have a broad network of sample providers and have our own setup to cut FFPE blocks, perform stainings, and our own pathologist to annotate samples for you. So you get the whole value chain from one hand: from sample to data production and analysis.
You receive a ranked target list with supporting evidence, full proteomic datasets, and a written interpretation you can bring straight into your next experiment.
Get in touch to discuss which layer of the proteome is most relevant to your target.
Typical study designs
- Differential proteomics for target nomination
- Target engagement / occupancy studies
- Cell-surface target discovery (ADCs, T-cell engagers)
- Pathway-based target prioritization
- Interaction-informed target validation
Let's plan your study
Every study that is executed incorrectly consumes valuable sample material, and, more importantly, wastes time and manpower. In our fast-paced scientific environment, these resources cannot be recovered.